Physician profile
DO-Eun Lee
NPI 1346339652
$62,447.98
in general payments reported to CMS, 2019-2025
61 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,431 · 2021: $3,428 · 2022: $4,928 · 2023: $22K · 2024: $11K · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $15K · Food and Beverage: $9,088 · Travel and Lodging: $4,918 · Consulting Fee: $4,824 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,010 · Education: $83.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,771.50 |
| Food and Beverage | $9,088.44 |
| Travel and Lodging | $4,918.21 |
| Consulting Fee | $4,824.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,010.00 |
| Education | $83.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20,585.31 | 2020-2023 | Tepezza |
| Amgen INC. | $10,147.97 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $7,960.89 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $5,656.28 | 2019-2020 | |
| Novo Nordisk INC | $2,919.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,693.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,593.23 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,501.13 | 2019-2024 | Enhertu |
| Insulet Corporation | $1,211.53 | 2019-2023 | Omnipod |
| Radius Health, INC. | $1,153.22 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $694.32 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $668.82 | 2019-2025 | Strensiq |
| Antares Pharma, INC. | $555.20 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $553.36 | 2019-2023 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $517.63 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $393.65 | 2019-2023 | Proclaim, Freestyle Libre 3 |
| Amarin Pharma, INC. | $308.68 | 2020-2021 | |
| Madrigal Pharmaceuticals | $237.95 | 2025 | Rezdiffra |
| Medtronic, INC. | $236.15 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Amneal Pharmaceuticals LLC | $225.00 | 2022 | |
| Ascend Therapeutics US, LLC | $218.92 | 2020-2023 | |
| Abbvie INC. | $203.89 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $191.34 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Medtronic Minimed, INC. | $168.95 | 2019 | |
| Ibsa Pharma INC. | $168.33 | 2019-2025 | Licart, Tirosint, Tirosint |
| Merck Sharp & Dohme LLC | $148.61 | 2019-2021 | |
| Dexcom, INC. | $141.19 | 2022-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $101.04 | 2022-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $87.53 | 2023-2024 | Ilet Bionic Pancreas |
| Biohaven Pharmaceutical Holding Company Ltd. | $85.08 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $84.94 | 2019 | |
| Currax Pharmaceuticals LLC | $83.05 | 2023 | Nexletol, Contrave, Nexlizet |
| Echosens North America, INC. | $81.62 | 2022-2023 | Fibroscan |
| Intra-Sana Laboratories | $80.11 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Tandem Diabetes Care, INC. | $77.30 | 2020-2022 | |
| Shire North American Group INC | $53.70 | 2019 | |
| Astellas Pharma US INC | $49.98 | 2024 | Veozah |
| Rgh Enterprises LLC | $48.94 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $45.70 | 2021 | |
| Verity Pharmaceuticals INC. | $43.42 | 2025 | Tlando |
| Zealand Pharma US, INC. | $42.63 | 2022 | |
| Embecta Corp. | $38.75 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Janssen Scientific Affairs, LLC | $38.38 | 2019 | |
| Ascendis Pharma Endocrinology INC | $28.70 | 2023 | |
| Sequel Med Tech, LLC | $27.61 | 2025 | Twiist |
| Kyowa Kirin, INC. | $24.14 | 2025 | |
| Daiichi Sankyo INC. | $24.07 | 2024 | Injectafer |
| Genzyme Corporation | $23.53 | 2024 | |
| Companion Medical, INC. | $22.48 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.30 | 2021 | |
| Esperion Therapeutics, INC. | $21.24 | 2021 | |
| Halozyme INC | $20.70 | 2023 | |
| Eisai INC. | $20.28 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $19.63 | 2025 | |
| Neurocrine Biosciences, INC. | $18.62 | 2025 | |
| Soleno Therapeutics, INC. | $15.30 | 2025 | Vykat Xr |
| Tolmar, INC. | $14.47 | 2025 | Jatenzo |
| Nevro Corp. | $13.80 | 2024 | Senza |
| Intuity Medical INC | $12.72 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,390.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw DO-Eun Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.